Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of KD025 in preparation of drugs for preventing and treating chronic renal fibrosis

A technology of renal fibrosis, medicine, applied in the field of medicine

Inactive Publication Date: 2019-09-06
NANJING CHILDRENS HOSPITAL
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This described use solves the technical problem that there is no suitable medicine in the prior art for reversing renal tubular epithelial cell fibrosis and treating chronic renal fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of KD025 in preparation of drugs for preventing and treating chronic renal fibrosis
  • Application of KD025 in preparation of drugs for preventing and treating chronic renal fibrosis
  • Application of KD025 in preparation of drugs for preventing and treating chronic renal fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 The therapeutic dose of KD025 has no toxic side effects on mice and cells

[0034] 1 Experimental materials and methods

[0035] 1) Administration, feeding and sampling of mice

[0036] The C57BL / 6 species male mice used in the present invention (7 weeks old at the time of purchase, body weight 20-24g) were purchased from the Experimental Animal Center of Nanjing Medical University, raised in an SPF level barrier environment of the Experimental Animal Center of Nanjing Medical University, and the animals were free to eat , maintaining a circadian rhythm of 12 hours of light and 12 hours of darkness. Laboratory temperature: 20-25°C, humidity 50±5%. The mice were randomly divided into control group (n=10) and KD025 group (n=10) after adaptive feeding for 1 week.

[0037] The present invention uses KD025 (purity ≥ 99%) purchased from Selleck Company. Dilute to 6 mg / ml with vehicle (5% DMSO, 35% PEG-300, 65% sterile saline) before administration. The dosage o...

Embodiment 2

[0044] Example 2 KD025 improves renal fibrosis in UUO model

[0045] 1 Experimental materials

[0046] The source of the C57BL / 6 species mouse and KD025 (purity ≥ 99%) used in the present invention is the same as that in Example 1.

[0047] 2 Experimental methods

[0048] 2.1 Animal administration, modeling and sampling

[0049] Twenty male C57BL / 6 mice (7 weeks old at the time of purchase, weighing 20-24g) were raised in an SPF-grade barrier environment in the Experimental Animal Center of Nanjing Medical University. The animals had free access to food and maintained a circadian rhythm of 12 hours of light and 12 hours of darkness. Laboratory temperature: 20-25°C, humidity 50±5%. The mice were randomly divided into control group (n=10) and KD025 group (n=10) after adaptive feeding for 1 week. After grouping, mice in the control group and mice in the KD025 group were intraperitoneally injected with vehicle or KD025 once a day, respectively, for a total of 8 injections. 24...

Embodiment 3

[0060] Example 3 KD025 reduces the expression level of fibrosis indicators in kidney tissue

[0061] 1. Experimental materials and methods

[0062] The source and use of mice and KD025 were as described in Example 2. The establishment method and tissue collection of the mouse UUO model are the same as in Example 2.

[0063] 1) RT-PCR

[0064] After RNAiso reagent from Takara company was used to extract the RNA in the sample according to the instructions, the RNA was reverse-transcribed into cDNA using the reverse transcription kit from Vazyme company, and SYBR green PCR mix combined with corresponding primers was used for RT-PCR detection.

[0065] 2) Statistical analysis

[0066] Histograms represent data using mean ± SEM. Analysis of variance (ANOVA) was used for comparison between multiple groups, and T test was used for data comparison between two groups. P<0.05 was regarded as statistically significant.

[0067] 2. Experimental results

[0068] In order to further ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of KD025 in preparation of drugs for preventing and treating chronic renal fibrosis, and especially relates to an application of KD025 in preparation of drugs for resistance of inflammation and protection of renal tubular epithelial cells. KD025 can alleviate the pathological changes of a mice model with chronic renal interstitial fibrosis, reduce the expression level of fibrosis factors in mice kidney tissues, reduce inflammatory reaction of kidney tissues and macrophages, protect the renal tubular epithelial cells in the fibrosis model and reverse transdifferentiation.

Description

technical field [0001] The invention belongs to the field of medicine, and specifically relates to the application of KD025 in the preparation of medicines for preventing and treating chronic renal fibrosis. KD025 prevents and treats chronic renal fibrosis through the dual mechanism of inhibiting renal tubular epithelial cell fibrosis and anti-inflammation. Background technique [0002] Chronic kidney disease (chronic kidney disease, CKD) is a worldwide public health problem. According to the epidemiological survey results in different regions, the incidence rate is between 8% and 16%. In our country, about 120 million people suffer from CKD. For decades, although people have extensively explored the pathogenesis and intervention strategies of CKD, so far, there is still a lack of effective means for the prevention and treatment of chronic kidney disease. A considerable number of CKD patients eventually develop into end-stage renal disease, requiring expensive Renal replace...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/517A61P13/12
CPCA61K31/517A61P13/12
Inventor 游然贾占军张爱华公伟于婧杨运文张玥李延伟周维
Owner NANJING CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com